ACHE and Alzheimer disease: The developments of acetylcholinesterase (AChE) inhibitors based on cholinergic hypothesis, such as rivastigmine, donepezil, tacrine, and galantamine, are only approved as therapeutic drugs for AD medical management, and reports revealed that AChE inhibitors exhibited short-term improvement in cognition dysfunctions [4,5,6,7].